Treatment of Ménétrier's disease with a monoclonal antibody against the epidermal growth factor receptor. Burdick JS, Chung E, Tanner G, Sun M, Paciga JE, Cheng JQ, Washington K, Goldenring JR, Coffey RJ (2000) N Engl J Med 343: 1697-701 Evidence for repatterning of the gastric fundic epithelium associated with Ménétrier's disease and TGFalpha overexpression. Nomura S, Settle SH, Leys CM, Means AL, Peek RM, Leach SD, Wright CV, Coffey RJ, Goldenring JR (2005) Gastroenterology 128: 1292-305 Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach. Coffey RJ, Washington MK, Corless CL, Heinrich MC (2007) J Clin Invest 117: 70-80 Efficacy of cetuximab in the treatment of Menetrier's disease. Fiske WH, Tanksley J, Nam KT, Goldenring JR, Slebos RJ, Liebler DC, Abtahi AM, La Fleur B, Ayers GD, Lind CD, Washington MK, Coffey RJ (2009) Sci Transl Med 1: 8ra18 Distinguishing Ménétrier's disease from its mimics. Rich A, Toro TZ, Tanksley J, Fiske WH, Lind CD, Ayers GD, Piessevaux H, Washington MK, Coffey RJ (2010) Gut 59: 1617-24 Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling. Myers MV, Manning HC, Coffey RJ, Liebler DC (2012) Mol Cell Proteomics 11: M111.015222 Chronic treatment of Ménétrier's disease with Erbitux: clinical efficacy and insight into pathophysiology. Settle SH, Washington K, Lind C, Itzkowitz S, Fiske WH, Burdick JS, Jerome WG, Ray M, Weinstein W, Coffey RJ (2005) Clin Gastroenterol Hepatol 3: 654-9 Roles for transforming growth factor-alpha in the stomach. Coffey RJ, Romano M, Goldenring J (1995) J Clin Gastroenterol 21 Suppl 1: S36-9 [18F]FLT-PET to predict pharmacodynamic and clinical response to cetuximab therapy in Ménétrier's disease. McKinley ET, Smith RA, Tanksley JP, Washington MK, Walker R, Coffey RJ, Manning HC (2012) Ann Nucl Med 26: 757-63
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.